诚意药业(603811) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥153,058,271.42, representing a year-on-year increase of 3.54%[5] - The net profit attributable to shareholders decreased by 17.77% to ¥32,684,974.03 compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses fell by 20.40% to ¥30,890,184.18[5] - Net profit for Q1 2024 was ¥32,730,039.82, a decrease of 17.5% from ¥39,622,334.78 in Q1 2023[22] - Earnings per share for Q1 2024 were ¥0.10, down from ¥0.12 in Q1 2023[23] - The company reported a tax expense of ¥4,925,117.54 for Q1 2024, compared to ¥2,340,068.07 in Q1 2023, indicating a significant increase[22] Cash Flow - The net cash flow from operating activities significantly decreased by 82.97% to ¥8,048,893.69[5] - Cash flow from operating activities for Q1 2024 was ¥8,048,893.69, significantly lower than ¥47,267,096.86 in Q1 2023[26] - The net cash flow from financing activities was negative at -$17,658,761.15 in Q1 2024, compared to a positive cash flow of $64,465,047.08 in Q1 2023, reflecting a significant decline[28] - The company raised $13,000,000.00 from borrowings in Q1 2024, a decrease of 93.2% compared to $190,000,000.00 in Q1 2023[28] - The company paid $27,213,613.99 in debt repayments during Q1 2024, down from $121,812,638.99 in Q1 2023, showing a reduction of about 77.7%[28] - The company’s cash outflow for dividend payments and interest was $3,457,541.95 in Q1 2024, slightly down from $3,705,891.63 in Q1 2023[28] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,877,300,840.15, a decrease of 0.82% from the end of the previous year[6] - Total liabilities decreased to ¥647,944,897.58 in Q1 2024 from ¥696,153,933.51 in Q1 2023, a reduction of 6.9%[22] - Current liabilities decreased from ¥342,648,100.70 to ¥295,950,168.06, a reduction of approximately 13.6%[17] - Long-term borrowings remained stable at around ¥316,363,014.42[17] Shareholder Information - Total number of common shareholders at the end of the reporting period is 15,712[12] - The largest shareholder, Yan Yiyi, holds 77,192,080 shares, accounting for 23.58% of total shares[12] Research and Development - Research and development expenses increased by 42.37%, primarily due to higher outsourced R&D costs and material inputs[9] - Research and development expenses increased to ¥11,781,100.15 in Q1 2024, compared to ¥8,275,164.89 in Q1 2023, marking a rise of 42.5%[22] Inventory and Receivables - Accounts receivable decreased from ¥76,768,569.65 to ¥64,681,142.41, a reduction of about 15.7%[16] - Inventory increased from ¥116,781,938.02 to ¥137,215,791.40, an increase of approximately 17.5%[16] - The company reported a significant increase in prepayments from ¥7,978,727.11 to ¥11,729,586.41, an increase of about 47.5%[16] Other Financial Metrics - The weighted average return on equity decreased by 0.89 percentage points to 2.70%[5] - The company reported a 101.89% increase in taxes and surcharges, mainly due to higher property tax and VAT[9] - Total operating costs for Q1 2024 were ¥127,302,359.23, up from ¥122,646,292.57 in Q1 2023, reflecting a rise of 3.3%[21] - Other comprehensive income after tax for Q1 2024 was ¥13,923.53, up from ¥1,591.30 in Q1 2023[23] - The company did not report any cash inflow from investments or acquisitions in Q1 2024, maintaining a consistent strategy from the previous year[28]